Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending doses of AZD3480 (ispronicline) in patients with schizophrenia on stable antipsychotic monotherapy
2006-004783-31Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ispronicline in schizophrenia (6 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of multiple ascending oral doses of AZD3480, Pharmacokinetic interaction between AZD3480 and quetiapine, risperidone or olanzapine and 1 more. Started Oct 2006; status: completed.
02
Drugs
ispronicline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2006-004783-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004783-31.